Press Releases

All Releases
View Summary Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time
Monday, January 8, 2018
PDF 16.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
Wednesday, January 3, 2018
PDF 9.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
Wednesday, January 3, 2018
PDF 12.4 KB Add to Briefcase
View Summary Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer
Tuesday, January 2, 2018
PDF 18.4 KB Add to Briefcase
View Summary Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration
Tuesday, December 19, 2017
PDF 21.7 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Monday, December 4, 2017
PDF 10.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Friday, November 10, 2017
PDF 11.8 KB Add to Briefcase
View Summary Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Thursday, November 9, 2017
PDF 103.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data
Tuesday, November 7, 2017
PDF 10.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Tuesday, November 7, 2017
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Announces Third Quarter 2017 Results and Provides Business Update
Monday, November 6, 2017
PDF 27.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
Monday, October 30, 2017
PDF 13.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018
Monday, October 23, 2017
PDF 14.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6
Thursday, October 19, 2017
PDF 9.9 KB Add to Briefcase
View Summary Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Wednesday, October 18, 2017
PDF 12.0 KB Add to Briefcase
View Summary Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Wednesday, October 11, 2017
PDF 13.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Thursday, September 21, 2017
PDF 10.0 KB Add to Briefcase
View Summary Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
Sunday, September 10, 2017
PDF 12.6 KB Add to Briefcase
View Summary Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
Sunday, September 10, 2017
PDF 16.3 KB Add to Briefcase
View Summary Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
Friday, September 1, 2017
PDF 14.9 KB Add to Briefcase
Showing 1-20 of 197 Page: 1 2 3 4 5 ... 10  Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
21.19
Change (%)
0.00
Volume
N/A

Data as of 4:15 PM ET on Friday, January 12, 2018
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.